Teva Capitalizes On Patent Expiry To Launch First Perforomist Rival
Analyst Projects Financial Hit For Originator Viatris
Teva has added to its vast portfolio in the US by introducing the first generic version of Viatris’ Perforomist for chronic obstructive pulmonary disease, as well as a generic of Soolantra to treat rosacea.
You may also be interested in...
Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.
Viatris’ share price closed the day nearly 15% down after announcing weaker than anticipated revenue, adjusted EBITDA and cash flow guidance for 2021. The market reacted strongly to the company’s expectations and ambitions, with management continuing to stress the strength of the combined Mylan and Upjohn businesses.
Collaboration partners Perrigo and Sol-Gel Technologies face legal action stemming from Perrigo’s filing of an ANDA for generic Duobrii lotion for the treatment of plaque psoriasis in adults.